Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29875066

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Jul
First author
Zhu AX

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jul;19(7):855-856. doi: 10.1016/S1470-2045(18)30383-8.
    note
    Source null
    related pmid
    29875067
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Sep;19(9):e440. doi: 10.1016/S1470-2045(18)30612-0.
    note
    Source null
    related pmid
    30191848
    relationship
    Erratum in

Authors and identifiers

  1. name
    Zhu AX
    type
    Author
  2. name
    Finn RS
    type
    Author
  3. name
    Edeline J
    type
    Author
  4. name
    Cattan S
    type
    Author
  5. name
    Ogasawara S
    type
    Author
  6. name
    Palmer D
    type
    Author
  7. name
    Verslype C
    type
    Author
  8. name
    Zagonel V
    type
    Author
  9. name
    Fartoux L
    type
    Author
  10. name
    Vogel A
    type
    Author
  11. name
    Sarker D
    type
    Author
  12. name
    Verset G
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Zhu AX
    type
    Author
  2. name
    Finn RS
    type
    Author
  3. name
    Edeline J
    type
    Author
  4. name
    Cattan S
    type
    Author
  5. name
    Ogasawara S
    type
    Author
  6. name
    Palmer D
    type
    Author
  7. name
    Verslype C
    type
    Author
  8. name
    Zagonel V
    type
    Author
  9. name
    Fartoux L
    type
    Author
  10. name
    Vogel A
    type
    Author
  11. name
    Sarker D
    type
    Author
  12. name
    Verset G
    type
    Author
bibliography ids
  1. nci-bib-67510ed597738b27f3e4124c
book metadata
content sha256
c5f8c9cf3eadb0c6e6df6ae88430f1cb3bba0bda2f6bff3bfb131bde3d578cbd
document type
citation
dois
  1. 10.1016/S1470-2045(18)30351-6
electronic publication date
display
2018 Jun 3
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29875066
immutable id
pubmed:29875066@c5f8c9cf3eadb0c6e6df6ae88430f1cb3bba0bda2f6bff3bfb131bde3d578cbd
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
940-952
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Jul;19(7):855-856. doi: 10.1016/S1470-2045(18)30383-8.
    note
    Source null
    related pmid
    29875067
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2018 Sep;19(9):e440. doi: 10.1016/S1470-2045(18)30612-0.
    note
    Source null
    related pmid
    30191848
    relationship
    Erratum in
outcomes validated
false
pmid
29875066
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
5d4aae7c324cb4aa6c581fe7004d483754d59329c20dc5ffa358611c123500a0
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Jul
precision
month
year
2018
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29875066/
title
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Preserved source evidence · Not medical advice